Clinical Trial: Effect of Mizagliflozin on Hypoglycemia in Patients With Post-Bariatric Hypoglycemia

U.S., Aug. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07760961) titled 'Effect of Mizagliflozin on Hypoglycemia in Patients With Post-Bariatric Hypoglycemia' on Aug. 07.

Brief Summary: VGX-001-013 (EMERGE) is a Phase 2b study to evaluate an investigational new drug, mizagliflozin, for safety, tolerability and its ability to prevent low blood sugar in patients with post-bariatric hypoglycemia.

Study Start Date: Oct., 2026

Study Type: INTERVENTIONAL

Condition: Postbariatric Hypoglycemia

Intervention: DRUG: Mizagliflozin 5 mg

5mg mizagliflozin capsules orally administered TID for 28 days

DRUG: Mizagliflozin 10 mg

10mg mizagliflozin capsules orally administered TID for 28 days

DRUG: Placebo

Place...